Protocol Ledger

NCT05092360 · Phase III · TERMINATED

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Interventional Phase III clinical trial protocol NCT05092360 sponsored by Mural Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-10 Enrollment: 456 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05092360
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)456 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05092360
Protocol FieldVerified Registry Value
NCT IdentifierNCT05092360
Consolidated Lead SponsorMural Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment456 participants (ACTUAL)
Registered Start Date2022-01-10
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI